



Lawsuit Filed to Stop the Recently Announced Most Favored Nation Model

Today, the Association of Community Cancer Centers (ACCC), the Global Colon Cancer Association, the National Infusion Center Association, and the Pharmaceutical Research and Manufacturers of America (PhRMA) initiated litigation in the United States District Court for the District of Maryland challenging the Trump Administration's Most Favored Nation interim final rule with comment period (IFC).

The lawsuit alleges that the IFC violates both Section 1115A of the Social Security Act (Center for Medicaid and Medicare Innovation authority) by establishing a mandatory, nationwide demonstration, and the Administrative Procedure Act by issuing a final rule without allowing meaningful public comment.

In addition to these concerns, the complaint states the "MFN Rule will irreparably harm patients, care providers, physicians, pharmaceutical manufacturers, and the broader public interest in innovation and discovery in the pharmaceutical field. The Rule will significantly harm patients; shortchange physicians and other healthcare providers, resulting in reduced access to covered drugs; force pharmaceutical manufacturers to accept steep price reductions and potentially delay launches in certain markets, further reducing patient access; and threaten long-term public health through cutbacks in research and development of new drugs."

The plaintiffs are seeking a preliminary and permanent injunction against the enforcement of the MFN Rule, including a temporary restraining order, a declaration that the MFN Rule is unconstitutional and invalid, and other appropriate relief.

The US Oncology Network will continue to work with all impacted stakeholders to support action to protect patient access to cancer treatments and the viability of community oncology practices.

To read a copy of the complaint, [CLICK HERE](#).

To read The Network's previous statement on the Most Favored Nation model, [CLICK HERE](#).